EGFR and neoplasm: Recently, Tu et al. [126] demonstrated that combined anti-PD-L1 and anti-CD73 therapy promoted T cell response to EGFR-mutant NSCLC and induced more tumor shrinkage compared with anti-PD-L1 or anti-CD73 treatment alone.